Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

3.16
+0.16005.33%
Pre-market: 3.170.0100+0.32%04:14 EST
Volume:756.94K
Turnover:2.37M
Market Cap:708.83M
PE:-2.37
High:3.18
Open:3.03
Low:3.03
Close:3.00
Loading ...

Company Profile

Company Name:
CureVac B.V.
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
1086
Office Location:
Friedrich-Miescher-Strasse 15,Tübingen,Baden-Württemberg,Germany
Zip Code:
72076
Fax:
- -
Introduction:
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Directors

Name
Position
Baron Jean Stephenne
Chairman and Supervisory Director
Friedrich von Bohlen und Halbach
Vice Chairman and Supervisory Director
Craig A. Tooman
Supervisory Director
Hans Christoph Tanner
Supervisory Director
Mathias Hothum
Supervisory Director
Ralf Clemens
Supervisory Director
Timothy M. Wright
Supervisory Director
Viola Bronsema
Supervisory Director

Shareholders

Name
Position
Franz Werner Haas
Chief Executive Officer
Pierre Kemula
Chief Financial Officer
Bernd Winterhalter
Chief Development Officer (Interim)
Florian von der Mulbe
Chief Production Officer
Igor Splawski
Chief Scientific Officer
Mariola Fotin Mleczek
Chief Technology Officer